Arcellx price target raised to $95 from $80 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Arcellx (ACLX) to $95 from $80 and keeps a Buy rating on the shares. The firm says preliminary results from iMMagine-1 are in-line with the initial results from anito-cel in Phase 1 at a similar time point, the analyst tells investors in a research note. The firm says that given this is an early look at the iMMagine-1 study with only half of the patients included in the analysis, it views he results as reinforcing of the anito-cel Phase 1 data and of the positive benefit observed.